Introduction {#Sec1}
============

Total hip arthroplasty (THA) is a well-known popular surgical procedure for hip diseases, including end-stage hip osteoarthritis and femur neck fracture \[[@CR1], [@CR2]\]. THA is a well-known cause of severe postoperative pain. Non-steroidal antiinflammatory drugs (NSAIDs) and morphine were commonly used for pain control in THA patients \[[@CR2]\]. These drugs were related to digestive tract side effects, and patients could not tolerate these complications \[[@CR3], [@CR4]\]. Thus, adequate pain control after THA is crucial for early ambulation and patient satisfaction.

Fascia iliaca compartment block (FICB) is an analgesic technique that involves injecting local anesthetic under the fascia of the iliacus muscle \[[@CR5], [@CR6]\]. FICB can be performed either guided by ultrasound or with a loss of resistance (LOR) technique. The evidence supporting FICB for pain control for THA patients is still not well established. Several RCTs have been published concerning FICB for THA patients. However, there was no consensus about the real efficacy of FICB in THA patients. Desmet et al. \[[@CR7]\] revealed that longitudinal suprainguinal FICB reduces postoperative morphine requirements after anterior approach THA. Perry et al. \[[@CR8]\] found that FICB has comparable pain control with psoas compartment block. The samples of published literature are limited, and the statistic power is limited. However, Aprato et al. \[[@CR9]\] revealed that intra-articular hip injection provides better pre-operatory pain management in elder patients with intracapsular hip fractures compared to the FICB.

Therefore, we performed a meta-analysis of randomized controlled trials to compare the effect of FICB versus control on the pain intensity and morphine consumption in patients undergoing THA. We hypothesized that FICB compared with placebo is associated with decreased pain intensity in patients undergoing THA. Additionally, we assessed the efficacy and safety of FICB with respect to morphine consumption, risk of fall, and nausea.

Materials and methods {#Sec2}
=====================

This meta-analysis was programed on the basis of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement guidelines \[[@CR10]\]. There was no registered protocol for this meta-analysis.

Search strategy {#Sec3}
---------------

We performed a systematic electronic search in PubMed, Embase, the Cochrane library, and Chinese Wanfang database from inception through September 1, 2018. We conducted electronic searches using exploded Medical Subject Headings (MeSH) terms and corresponding key words. The search terms used in PubMed were listed in Additional file [1](#MOESM1){ref-type="media"}. No language restriction was applied. We also manually checked the bibliographies of previous reviews and included trials to identify other potentially eligible trials.

Inclusion criteria {#Sec4}
------------------

Published RCTs meeting the following criteria were included: (1) population: adult patients and prepared for THA, (2) intervention: single administration FICB for pain control, (3) comparison: placebo or saline, and (4) ≥ 1 of the following outcomes: visual analog scale (VAS) at 6--8 h, 12 h, 24 h, and 48 h; total morphine consumption; occurrence of nausea; and occurrence of fall.

Study selection {#Sec5}
---------------

After the duplicates were removed and the study selection process was completed, the titles and abstracts were scanned by two independent investigators. The relevant data were extracted by adopting a predetermined standardized procedure, which involved the first authors, year of publication, country, demographic characteristics of the participants, and the treatment regimen for each group. All data were verified for internal consistency, and controversies were settled by consensus or discussion with a third author. When inadequate information existed in the studies, contacting the first authors to obtain and clarify the relevant data were essential as specified by the standardized protocol.

Quality assessment {#Sec6}
------------------

Cochrane collaboration's tool for assessing the risk of bias was used to evaluate methodological quality of included trials. This tool focuses on the internal validity of the trial and assessment of risk of possible bias in different phases of trial conduct. The following items were assessed: random sequence generation, allocation concealment, blinding of participants, personnel and outcome assessment, incomplete outcome measures, selective outcome reporting, and other types of bias. Each item was qualified as low risk (L), unclear risk (U), or high risk (H). All assessments were conducted by two reviewers, independent of each other. Controversies were settled by consensus or discussion with a third author.

Data extraction {#Sec7}
---------------

Two authors independently extracted the information from the original studies using a standardized data abstraction list, including study characteristics (such as author, publication year, country), patient characteristics (such as number of patients, mean age, gender, and female patients), intervention details for each treatment group (intervention type, dose, drugs and regimens), and outcome measures (VAS at 6--8 h, 12 h, 24 h, 48 h; total morphine consumption; occurrence of nausea; and occurrence of fall). Data were abstracted from the article text, tables, and graphs.

Data synthesis and statistical methods {#Sec8}
--------------------------------------

In this meta-analysis, effect sizes for dichotomous outcomes were expressed as relative risk (RR) with 95% confidence interval (CI). Mean difference (MD) and 95% CI were calculated for continuous outcomes. The effect sizes were computed by a random-effects model \[[@CR11]\]. *I*^2^ statistic was used to estimate the heterogeneity, with values greater than 50% considered as significant heterogeneity \[[@CR12]\]. Furthermore, we applied sensitivity analyses to verify the robustness of the study results by using removing trials one by one. Egger linear regression test and funnel plots were implemented to test the publication bias when more than ten publications were included \[[@CR13]\]. *P* values \< 0.05 denoted statistically significant differences. Data analysis was conducted with Stata 12.0 (Stata Corp., College Station, TX, USA).

Results {#Sec9}
=======

Search results {#Sec10}
--------------

The PRISMA statement flowchart shows the process of literature screening, study selection, and reasons for exclusion (Fig. [1](#Fig1){ref-type="fig"}). Our initial search yielded 556 potential studies. After removing duplicates by Endnote Software (Version X7, Thompson Reuters, CA, USA) and screening the titles and abstracts, eight RCTs were included in this meta-analysis \[[@CR7], [@CR14]--[@CR20]\].Fig. 1Flow diagram of the study selection process

General characteristic {#Sec11}
----------------------

Characteristics and demographics of the included studies were presented in Table [1](#Tab1){ref-type="table"}. These trials were published from 2009 to 2017. Population sizes ranged from 11 to 43, with a total of 372 patients (FICB = 186, control = 186). In the included studies, age ranged from 54 to 71.2 years. Protocol of FICB included ropivacaine and bupivacaine combined with or no epinephrine. Dose of infiltration drugs ranged from 30 to 50 ml. Only one study reported complication (hematoma) about FICB. Most of the included studies were performed with a relative short follow-up.Table 1General characteristic of the included studies. FICB, fascia iliaca compartment blockAuthorCountrySize (*n*)Age (years)Female (%)InterventionControlNature of studyComplicationsTechniqueAnesthesiaFollow-upShariat 2013USA16/1661.056.230 mL 0.5% ropivacainePlaceboRCTNSParallelGANSStevens 2007Australia22/2254.250.040 mL mixture of 30 mL of 0.5% bupivacaine with 1:200000 epinephrine and 150 μg of clonidinePlaceboRCTNSPerpendicularSAAt dischargeDesmet 2017Belgium43/4267.565.440 mL of ropivacaine 0.5%PlaceboRCTNSPerpendicularGA6 monthsBang 2016Korea11/1181.685.240 mL of ropivacaine 0.2% with epinephrine 5 mg/mLPlaceboRCTNSParallelGANSGoitia 2009Spanish21/2055.655.040 ml of 5% bupivacainePlaceboRCTNSParallelNSNSDeniz 2014Turkey20/2059.156.52% prilocaine, 30 ml of 0.25% bupivacaine (1 mg/kg)PlaceboRCTNSPerpendicularGA3 daysCucereanu Badica 2010Romania30/ 3271.035.450 mL of ropivacaine 0.2% with epinephrinePlaceboRCTNSPerpendicularGANSLei 2016China23/2368.745.240 ml of 5% bupivacainePlaceboRCTHematoma (*n* = 1)ParallelGA2 days

Risk of bias {#Sec12}
------------

Figures [2](#Fig2){ref-type="fig"} and [3](#Fig3){ref-type="fig"} describe the risk of bias summary and risk of bias graph, respectively. Overall, two trials were categorized as being at low risk of bias, four as being unclear, and two as being at high risk of bias.Fig. 2Risk of bias summaryFig. 3Risk of bias graph

Results of meta-analysis {#Sec13}
------------------------

### VAS at 1--8 h, 12 h, 24 h, and 48 h {#Sec14}

The VAS pain scores after treatment for 1--8 h weeks were reported in four trials. There was a little heterogeneity between the included studies (*I*^2^ = 9.3%, *P* = 0.356); fixed-effects model was adapted to analyze the results. The result revealed that that FICB was superior to control in terms of VAS pain scores after intervention for 1--8 h (WMD = − 0.78, 95% CI \[− 1.01, − 0.56\], *P* = 0.000, Fig. [4](#Fig4){ref-type="fig"}a). There was a large heterogeneity between the included studies for VAS pain scores after treatment for 12 h (*I*^2^ = 81.7%, *P* = 0.000, Fig. [4](#Fig4){ref-type="fig"}b), 24 h (*I*^2^ = 73.6%, *P* = 0.001, Fig. [4](#Fig4){ref-type="fig"}c), and 48 h (*I*^2^ = 92.8%, *P* = 0.000, Fig. [4](#Fig4){ref-type="fig"}d). Random-effects model was performed for VAS pain score at 12 h, 24 h, and 48 h. Results have shown that FICB has a beneficial role in reducing VAS pain scores at 12 h (WMD = − 0.69, 95% CI \[− 1.22, − 0.16\], *P* = 0.011, Fig. [4](#Fig4){ref-type="fig"}b) and 24 h (WMD = − 0.46, 95% CI \[− 0.89, − 0.02\], *P* = 0.039, Fig. [4](#Fig4){ref-type="fig"}c). Pooled data found that no statistically significant difference was observed between the FICB group and the control group in terms of the VAS scores after treatment for 72 h (WMD = − 0.52, 95% CI \[− 1.31, 0.28\], *P* = 0.203, Fig. [4](#Fig4){ref-type="fig"}d).Fig. 4Forest plot for the comparison of VAS at 1--8 h (**a**), VAS at 12 h (**b**), VAS at 24 h (**c**), and VAS at 48 h (**d**) between the FICB group and the control group

### Total morphine consumption {#Sec15}

A total of five studies reported total morphine consumption between the FICB group and the control group. We applied a random-effects model to analyze the results since there was a large heterogeneity between the included studies (*I*^2^ = 80.01%, *P* = 0.000). The result shows that the FICB could significantly reduce total morphine consumption than the control group (WMD = − 23.35, 95% CI \[− 40.53, − 6.18\], *P* = 0.008, Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Forest plot for the comparison of total morphine consumption between the FICB group and the control group

### Length of hospital stay {#Sec16}

A total of five studies reported the length of hospital stay between the FICB group and the control group. We applied a fixed-effects model to analyze the results since there was no heterogeneity between the included studies (*I*^2^ = 0.0%, *P* = 0.796). The result shows that the FICB could significantly reduce the length of hospital stay than the control group (WMD = − 0.97, 95% CI \[− 1.34, − 0.60\], *P* = 0.000, Fig. [6](#Fig6){ref-type="fig"}).Fig. 6Forest plot for the comparison of the length of hospital stay between the FICB group and the control group

### The occurrence of nausea {#Sec17}

Six studies involving 179 patients were available for analysis of the occurrence of nausea. The FICB led to significantly less occurrence of nausea than the control group (RR = 0.44, 95% CI \[0.28 to 0.70\], *P* = 0.000; *I*^2^ = 0.0%, *P* = 0.984, Fig. [7](#Fig7){ref-type="fig"}). Thus, we used a fixed-effects model to pool the relevant data.Fig. 7Forest plot for the comparison of risk of nausea between the FICB group and the control group

### The occurrence of fall {#Sec18}

Six studies provided data on the occurrence of fall. FICB was not associated with an increase of the occurrence of fall (RR = 0.72, 95% CI \[0.41 to 1.27\], *P* = 0.260 Fig. [8](#Fig8){ref-type="fig"}). There was no heterogeneity between the included studies (*I*^2^ = 0.0%, *P* = 0.998); thus, we used a fixed-effects model to pool the occurrence of fall.Fig. 8Forest plot for the comparison of the occurrence of fall between the FICB group and the control group

### Publication bias, sensitivity analysis, and subgroup analysis {#Sec19}

The funnel plot (Fig. [9](#Fig9){ref-type="fig"}) and Begg's test (Fig. [10](#Fig10){ref-type="fig"}) showed no publication bias in the included studies.Fig. 9Funnel plot for the comparison of the VAS at 1--8 h between the FICB group and the control groupFig. 10Begg's test for the comparison of the VAS at 1--8 h between the FICB group and the control group

Sensitivity analysis was performed by excluding one trail in turn and recalculating the pooled WMD for the remaining trials, which found that none of the studies affected the result (Fig. [11](#Fig11){ref-type="fig"}).Fig. 11Sensitivity analysis of the VAS at 6--8 h between the FICB group and the control group

Discussion {#Sec20}
==========

Principal findings {#Sec21}
------------------

The pooled results indicate that, according to available evidence, THA patient administration with FICB was associated with a reduction of pain intensity up to 24 h. What is more, FICB could significantly reduce total morphine consumption and the risk of nausea. However, there was no significant difference between the FICB and the control in the pain intensity at 48 h and risk of fall.

Relation to other systematic reviews {#Sec22}
------------------------------------

There were two meta-analyses comparing FICB and placebo that have been published \[[@CR21], [@CR22]\]. Zhang et al. \[[@CR21]\] found that FICB has a beneficial role in controlling pain in total hip and knee arthroplasties. Limitation of this meta-analysis was obvious; THA and total knee arthroplasty were two different surgeries, and thus, pain intensity was different. Fei et al. \[[@CR22]\] conducted a meta-analysis about FICB for pain control in lower limb surgery. Mixed different surgeries cause large clinical heterogeneity. In comparison, the current meta-analysis focused on THA only.

Implications for clinical practice {#Sec23}
----------------------------------

Our meta-analysis showed that the pain benefit existed in FICB compared with placebo. As we know, the femoral nerve and the lateral femoral cutaneous nerve innervate with the hip joint. FICB is injected through the iliac fascia cavity, which is constructed with the fascia as prezone and the iliopsoas as posterior. FICB could significantly block the femoral nerve, lateral femoral cutaneous nerve, and obturator nerve. Thus, FICB could decrease the pain intensity after THA. This beneficial effect was identified by previous trials. Besides, FICB is easy to administer, as it only requires ultrasound guidance. Steenberg et al. \[[@CR23]\] performed a systematic review and revealed that FICB is an effective and relatively safe supplement in the preoperative pain management of hip fracture patients. The main outcome was consistent with our conclusion. Considering the results of the current meta-analysis and published studies, we suggest the administration FICB for pain control for THA patients.

Moreover, FICB could significantly decrease the morphine consumption and morphine-related complication (occurrence of nausea). McGraw-Tatum et al. \[[@CR24]\] identified that FICB required less overall total opioids than the control group. And FICB is a relatively safe anesthesia technique as the needle point is away from the femoral nerve, femoral artery, and femoral vein \[[@CR25]\].

Limitations {#Sec24}
-----------

The present meta-analysis has some existing limitations that should be noted. First, only seven RCTs were included in this meta-analysis, and more high-quality studies are needed to confirm the above conclusions in the future. Second, patients were administered with different dose and regimes of FICB, which may lead to large heterogeneity. Third, the follow-up time in the included RCT was limited, and therefore, some adverse events may be underestimated. Fourth, a functional outcome is not performed due to the insufficiency of relevant data; future studies should observe the effects of FICB for hip function.

Conclusion {#Sec25}
==========

Our meta-analysis suggested that FICB but not placebo significantly reduced postoperative pain for THA patients. The use of FICB significantly reduced morphine consumption and the risk of nausea. FICB is recommended as an adjunct to multimodal anesthesia for THA patients. Future studies should explore optimal strategies (including drug and volume) of FICB.
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===============

 {#Sec26}
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